Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Ripple Therapeutics Corporation is currently overseeing 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. The prosecution for this portfolio is distributed across 4 distinct examiners. These matters are situated within 4 distinct art units, indicating that the company's technical innovations are being reviewed by several specialized groups. This variety of examiners and art units requires a coordinated strategy to maintain consistency across the patent office.
The busiest examiner for this portfolio is HOLLOMAN, NANNETTE, who is responsible for 1 pending office action. As an examiner involved, HOLLOMAN, NANNETTE serves as a point of contact for the applicant. For a patent practitioner, this environment requires managing relationships with the assigned personnel. The practitioner must tailor their responses to the expectations of the experts within the Biotechnology & Pharmaceuticals field. This structure involves administrative tracking of the 1 pending matter assigned to the busiest examiner while the total volume is 4 pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §112 only | 1 (25%) |
| Double-patenting + other | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOLLOMAN, NANNETTE | 1 | 60.7% | +23.1% |
| AGGARWAL, SAHIL CHANDER | 1 | 66.7% | +0.0% |
| HIRT, ERIN E | 1 | 40.6% | +22.9% |
| MCDOWELL, BRIAN E | 1 | 74.0% | +31.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17629733 | DIMER COMBINATIONS AND USES THEREOF | MCDOWELL, BRIAN E | 8d overdue |
| 18992519 | COMPOSITIONS AND METHODS FOR IMPROVING VISION | HOLLOMAN, NANNETTE | — |
| 18738907 | DEXAMETHASONE PRODRUG COMPOSITIONS AND USES THEREOF | HIRT, ERIN E | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| 1623 | 1 |
| 1616 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18992519 | COMPOSITIONS AND METHODS FOR IMPROVING VISION | HOLLOMAN, NANNETTE | 1612 | §103 | Non-Final OA | — | Pending | Jan 08, 2025 |
| 18792949 | HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | AGGARWAL, SAHIL CHANDER | 1623 | §112DP | Non-Final OA | — | Pending | Aug 02, 2024 |
| 18738907 | DEXAMETHASONE PRODRUG COMPOSITIONS AND USES THEREOF | HIRT, ERIN E | 1616 | §103DP | Non-Final OA | — | Pending | Jun 10, 2024 |
| 17629733 | DIMER COMBINATIONS AND USES THEREOF | MCDOWELL, BRIAN E | 1624 | §112 | Non-Final OA | 8d overdue | Pending | Jan 24, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRipple Therapeutics Corporation has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Nannette Holloman has the most, with 1 of Ripple Therapeutics Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
